Vident Investment Advisory’s Mesoblast MESO Stock Holding History

Vident Investment Advisory’s Portfolio MESO Stock Details MESO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-18,207	Closed	-$142K	–	621
2023 Q2	$142K	Buy	18,207 +199	+1%	+$1.42K	﹤0.01%	1102
2023 Q1	$118K	Buy	18,008 +3,968	+28%	+$26.3K	﹤0.01%	1158
2022 Q4	$81.7K	Buy	14,040 +1,595	+13%	+$9.97K	﹤0.01%	1120
2022 Q3	$0	Buy	+12,445	New	+$75.2K	﹤0.01%	1233

Other funds holding MESO

Penbrook Management New York $132M AUM 29.91% 1-Year Est. Return

LCM

Lazari Capital Management Woodland Hills, California $287M AUM 28.24% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

PWM

Prosperity Wealth Management San Ramon, California $300M AUM 28.11% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Vident Investment Advisory's MESO Position: Q3 2023 in Review

Vident Investment Advisory sold out of Mesoblast (MESO) in Q3 2023, closing a stake of 18,207 shares — an estimated $142K sold.

Vident Investment Advisory first reported a position in MESO in Q3 2022 and held it in 4 quarters. The position peaked at $142K in Q2 2023. 35 funds tracked by Wall St. Rank hold MESO as of Q3 2023.

Vident Investment Advisory reported no remaining Mesoblast position as of Q3 2023 after selling out during the quarter.
Vident Investment Advisory sold 18,207 Mesoblast shares in Q3 2023, an estimated $142K.
Vident Investment Advisory first reported a position in Mesoblast in Q3 2022 and held it in 4 quarters.
Vident Investment Advisory's Mesoblast position peaked at $142K in Q2 2023.
35 funds tracked by Wall St. Rank held Mesoblast as of Q3 2023.

Based on Vident Investment Advisory's 13F filing for Q3 2023.